Rigel Pharmaceuticals (RIGL) Fundamental Analysis: Revenue, Earnings & Valuation

3.62 / 10

Netural

Fundamental metrics score 3.6/10, yielding a neutral rating. Strengths include a low cost‑of‑sales ratio (6.67%) and a healthy current‑liabilities‑to‑total‑liabilities ratio (81.3%). However, a high long‑term‑debt‑to‑working‑capital ratio and modest interest coverage raise concerns.

Analysis Checks(9/10)

Revenue-MV

Value-0.49

Score2/3

Weight22.37%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value64.15

Score2/3

Weight0.48%

1M Return0.13%

Inventory turnover ratio

Value2.24

Score2/3

Weight-4.02%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value81.27

Score2/3

Weight1.36%

1M Return0.36%

PB-ROE

Value0.43

Score2/3

Weight32.89%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.16

Score1/3

Weight-2.37%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.48

Score2/3

Weight-4.09%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value64.15

Score2/3

Weight0.20%

1M Return0.05%

Cost of sales ratio (%)

Value6.67

Score3/3

Weight1.02%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight52.15%

1M Return11.12%

Is RIGL undervalued or overvalued?

RIGL scores 3.62/10 on fundamentals and holds a Fair valuation at present. Backed by its 185.94% ROE, 124.72% net margin, 1.38 P/E ratio, 1.30 P/B ratio, and 1960.61% earnings growth, these metrics solidify its Netural investment rating.